Literature DB >> 28154998

Upregulated expression of substance P (SP) and NK1R in eczema and SP-induced mast cell accumulation.

Mengmeng Zhan1, Wenjiao Zheng1, Qijun Jiang2, Zuotao Zhao3, Zhiyun Wang1, Junling Wang1, Huiyun Zhang1,4, Shaoheng He5.   

Abstract

Substance P (SP) was reported to be associated with eczema and acts as a potent skin mast cell secretagogue. However, little is known of its expression in inflammatory cells in eczema and its ability in induction of mast cell accumulation. In the present study, we investigated expression of SP and neurokinin-1 receptor (NK1R) on peripheral blood leukocytes and mast cells from patients with eczema and influence of SP on mast cell accumulation by using flow cytometry analysis, trans-epithelial cell migration assay and mouse peritoneal model. The results showed that plasma SP and IL-17A levels in eczema patients were higher than that in healthy control subject. The percentages of SP+ and NK1R+ expression populations of monocytes, helper T cells, natural killer T cells and basophils in peripheral blood of eczema patients were markedly elevated. It was observed that not only absolute number of mast cells but also SP+ and NK1R+ mast cells are enhanced in the lesion skin of eczema. SP showed a potent chemoattractant action on mast cells as assessed by a mouse peritoneal model and a trans-endothelium cell migration assay. SP-induced mast cell accumulation appears a CD18/CD11a complex, L-selectin and ICAM-1-dependent event which can be blocked by a NK-1R antagonist RP67580. In conclusion, elevated expression of SP in patients with eczema and the ability of SP in induction of mast cell accumulation indicate strongly that SP is a potent proinflammatory mediator, which contributes to the pathogenesis of eczema. Inhibitors of SP and blockers of NK1R are likely useful agents for treatment of eczema.

Entities:  

Keywords:  Eczema; IL-17; Mast cell; NK1R; Substance P

Mesh:

Substances:

Year:  2017        PMID: 28154998     DOI: 10.1007/s10565-016-9379-0

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  7 in total

1.  Reply to Fattori et al.: Action of SP and IL-33 on mast cells.

Authors:  Theoharis C Theoharides; Alexandra Taracanova; Irene Tsilioni; Pio Conti; Susan E Leeman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

2.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

3.  Enhanced Expression of IL-18 and IL-18BP in Plasma of Patients with Eczema: Altered Expression of IL-18BP and IL-18 Receptor on Mast Cells.

Authors:  Yalin Hu; Junling Wang; Huiyun Zhang; Hua Xie; Weiwei Song; Qijun Jiang; Nan Zhao; Shaoheng He
Journal:  Mediators Inflamm       Date:  2017-08-03       Impact factor: 4.711

Review 4.  Skin microbiome & host immunity: applications in regenerative cosmetics & transdermal drug delivery.

Authors:  Kavita Beri
Journal:  Future Sci OA       Date:  2018-03-28

Review 5.  The skin microbiome: impact of modern environments on skin ecology, barrier integrity, and systemic immune programming.

Authors:  Susan L Prescott; Danica-Lea Larcombe; Alan C Logan; Christina West; Wesley Burks; Luis Caraballo; Michael Levin; Eddie Van Etten; Pierre Horwitz; Anita Kozyrskyj; Dianne E Campbell
Journal:  World Allergy Organ J       Date:  2017-08-22       Impact factor: 4.084

6.  Neuropeptide Initiated Mast Cell Activation by Transcutaneous Electrical Acupoint Stimulation of Acupoint LI4 in Rats.

Authors:  Li-Zhen Chen; Yu Kan; Zhi-Yun Zhang; Yi-Li Wang; Xiao-Ning Zhang; Xiao-Yu Wang; Wei He; Xiang-Hong Jing
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

Review 7.  The Role of Mast Cells in IgE-Independent Lung Diseases.

Authors:  Daniel Elieh Ali Komi; Esmaeil Mortaz; Saeede Amani; Angelica Tiotiu; Gert Folkerts; Ian M Adcock
Journal:  Clin Rev Allergy Immunol       Date:  2020-06       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.